RE: MAKING PROGRESS11 Nov 2025 08:12
Hemogenyx Pharmaceuticals' CEO, Dr. Vladislav Sandler, has confirmed the company is in ongoing discussions with multiple large pharmaceutical companies regarding potential partnerships, joint ventures, or a possible acquisition for its lead CAR-T therapy, HG-CT-1.
The specific identity of these "big pharma" companies and the details of the negotiations are not publicly disclosed due to confidentiality agreements (NDAs).
Key Details:
✅️ .Ongoing Discussions: Dr. Sandler has explicitly stated that he is in discussions with "Pharmaceutical companies" that means more than one company is in talks after understanding & seen the data. Right ✅️
✅️ Confidentiality: The nature of these talks is highly confidential, and the "first time" retail investors are likely to hear concrete news will be through an official regulatory news announcement (RNS) if a deal is reached.✅️
Potential Deal Structure: Discussions could lead to various outcomes, including:
.A joint venture (JV). ✅️
.Upfront payments and milestone payments. ✅️
.A full acquisition or buy-out of the company or specific assets.✅️
Driving Factors: The discussions are likely spurred by positive, early safety and efficacy signals from the ongoing Phase I clinical trial of HG-CT-1 for relapsed/refractory Acute Myeloid Leukemia (R/R AML).👍
Recent Milestones: Recent developments, such as the clearance for pediatric enrollment and a manufacturing partnership with Made Scientific, are seen as positive steps that make the company a more attractive partner for major pharmaceutical firms.👍
Timeline: While a timeline for a deal is not confirmed, many of us shareholders are speculating that a positive RNS could be forthcoming once more clinical data is available, particularly from the higher-dose adult cohort or the first pediatric patient which is very soon now...👍
As soon as we get the data from P4 and the 1st pediatric patient the better the shareprice will be I mean it will fly like a rocket and the price tag reflect the results and we the the shareholders will be rewarded accordingly. ✅️
So just watch this space it's been over 2 weeks now since Vlad's video was released, I expect some major progress has been made as he now knows the science works very well from the successful results already observed in 3 patients at a lower dose level.
With over £2 million in the bank now so, no need for any more funds for now and if Hemo needs any funds going forward it will be in a non dilution format. The model and road map is clearly clear as day now, what more can an investor ask for.
Low operating costs model now ✅️
Money in the bank ✅️
The science works ✅️
Bargain shareprice now under 2p = big returns 💰
Awaiting the big go ahead P4, 1st pediatric patient treated, JV ✅️
I expect a blockbuster RNS to land very soon and the pulled back spring coiled shareprice will pop blowing the doors off and the sh
Sign In
Follow the stocks
